SUMMARY Electrophysiological studies were performed in 22 patients with intraventricular conduction delay before and after intravenous infusion of disopyramide (Norpace), 2 mg/kg. Mean control maximal sinus node recovery time (1039 ± 187 msec), atrioventricular nodal conduction time (113 + 28 msec), and atrioventricular nodal effective refractory periods (349 ± 67 msec) did not change significantly after administration of disopyramide (1073 
SUMMARY Electrophysiological studies were performed in 22 patients with intraventricular conduction delay before and after intravenous infusion of disopyramide (Norpace), 2 mg/kg. Mean control maximal sinus node recovery time (1039 ± 187 msec), atrioventricular nodal conduction time (113 + 28 msec), and atrioventricular nodal effective refractory periods (349 ± 67 msec) did not change significantly after administration of disopyramide (1073 ± 284 msec, 112 ± 31 msec, and 342 ± 42 msec, respectively). Mean spontaneous cycle length (756 ± 146 msec) decreased significantly 5 minutes after disopyramide (717 ± 124 msec) (p < 0.05), but not after 30 minutes (734 ± 142 msec). A small but statistically significant (p < 0.05) increase occurred after disopyramide in the mean atrial effective refractory period (259 + 51 to 280 ± 53 msec), ventricular effective refractory period (253 ± 23 to 275 ± 33 msec), as well as the relative refractory period of the ventricular specialized conduction system (six patients) (433 ± 78 to 479 ± 62 msec). Although mean control infranodal conduction time (67 ± 35 msec) increased 5 minutes after disopyramide (79 i 41 msec) (p < 0.001) (18%), no spontaneous episodes of second-degree or third-degree atrioventricular block were observed. In six patients with premature ventricular depolarizations (. 1/min), the arrhythmia was totally abolished in four, markedly reduced in one, and remained unchanged in one. Disopyramide resulted in significant prolongation of infranodal conduction time as well as in atrial and ventricular refractoriness, but nevertheless appears to be safe in patients with bundle branch block.
DISOPYRAMIDE PHOSPHATE (Norpace) is
effective for treatment of cardiac arrhythmias.' 20 In vitro microelectrode studies have shown that this agent has electrophysiological properties similar to quinidine. 21 Electrophysiological studies in animals showing that disopyramide is associated with prolongation of atrial and ventricular refractoriness as well as atrioventricular (AV) conduction21'24 are consonant with these observations. Recent studies of disopyramide in man have generally demonstrated increased atrial and ventricular refractoriness and variable effects on AV conduction. [25] [26] [27] [28] [29] [30] [31] The various effects of disopyramide have been attributed to both direct and vagolytic actions. The reported prolongation of infranodal conduction time in several clinical studies25' 31 prompted the suggestion that this agent is contraindicated in patients with intraventricular conduction disturbances. 23 No comprehensive study of this drug in patients with AV or intraventricular conduction delay is currently available. In this study we assessed the electrophysiological effects and safety of intravenous disopyramide in patients with bundle branch block.
Materials and Methods
Twenty-two patients with right or left bundle branch block and 1: 1 AV conduction were included in the study. We excluded patients with bundle branch block and recent acute myocardial infarction or those showing second or third degree AV block before study. These studies were performed according to protocol approved by the Committee of Human Experimentation of the University of California, San Francisco.
All studies were performed in the cardiac catheterization laboratory with the patients in a nonsedated, postabsorptive state. All cardiac drugs were terminated within three half-lives of those agents (except for one instance in which procainamide was inadvertently continued until 18 hours before study). Two ous electrocardiographic recordings were made to assess the frequency of ventricula; premature depolarizations. Atrial overdrive pacing was instituted beginning at cycle lengths approximately 50 msec below the spontaneous cycle length, and the paced cycle length was decreased by 50 msec decrements until AV nodal Wenckebach conduction was achieved. The sinus node recovery time (SNRT) and abnormalities in postpacing cycle lengths (2-10, secondary pause) were determined after 1 minute of pacing at each paced cycle length as described previously.34 Progressively premature atrial depolarizations at 10 msec decrements were inserted (Bloom Programmable Stimulator, Bloom and Associates, Warketh, PA) throughout the atrial diastolic cycle at paced cycle lengths of 500 msec. Twelve patients underwent both ventricular overdrive pacing and premature ventricular stimulation as just described. After completion of control observations, 2 mg/kg of disopyramide were infused intravenously over 7 minutes. (Blood disopyramide concentrations in the 2-4 ,ug/ml range were considered therapeutic. 35' 36) Five minutes after completion of the infusion, heart rate, blood pressure, A-H, H-Q, and serum disopyramide levels were measured. Atrial (16 patients) and ventricular (12 patients) pacing studies were repeated beginning 10 minutes after termination of the infusion and were completed within 30 minutes. Heart rate, blood pressure, A-H, H-Q, and serum levels of disopyramide were again measured 30 minutes after termination of the infusion. The data were analyzed using the t test for paired data.
Definitions
The A-H interval was measured from the initial rapid deflection of the low right atrial electrogram to the initial deflection of the His bundle depolarization (normal range 60-120 msec).
The H-Q interval was measured from the initial His deflection to the earliest onset of ventricular activation detected on the surface electrogram (normal range 35-55 msec); S,S, refers to the driven cycle length, and S2 refers to the premature stimulus.
The functional refractory period of atrium is defined as the shortest attainable A1A2 for any S,S,.
The effective refractory period of atrium is defined as the longest SSS2 that does not result in atrial depolarization.
The functional refractory period of the AV node is defined as the shortest H1H2 interval resulting from any two consecutive propagated atrial depolarizations.
The effective refractory period of the AV node is defined as the longest A1A2 interval at which A2 does not propagate to the His-Purkinje system.
The relative refractory period of the His-Purkinje system is defined as the longest H1H2 interval at which H2 conducte to the ventricle with a longer H-Q interval than that of the basic drive beat or with a QRS of aberrant morphology.
The effective refractory period of the His-Purkinje system is defined as the longest H1H2 interval at which H2 fails to depolarize the ventricles. The His-Purkinje system was considered as a single functioning unit for the purpose of this study.
The effective refractory period of ventricle is defined as the longest SjS, interval during ventricular pacing with ventricular premature depolarization at which S2 fails to produce a ventricular depolarization.
Results
The relevant clinical and electrophysiological data are summarized in tables 1 and 2. Control 5 30 MINUTES FIGURE 1. Effects of intravenous administration of disopyramide, 2 mg/kg, on infranodal conduction (H-Q) in 22 patients with intraventricular conduction delay at S and 30 minutes after infusion. Maximal H-Q prolongation is seen S minutes after infusion.
opyramide, mean H-Q (75 + 36 msec) decreased slightly compared with the 5-minute determination (p < 0.02) ( fig. 1 ), but was still significantly greater than the control valve (p < 0.001). There was no significant difference in either the absolute or mean percent H-Q increment after disopyramide between patients with normal H-Q intervals compared with patients with prolonged H-Q intervals. No spontaneous progression to second or third degree AV block was observed after disopyramide even in patients with marked prolongation of infranodal conduction time ( fig. 2) overdrive pacing resulted in infranodal Wenckebach and 2:1 infranodal block after disopyramide ( fig. 3 ).
His-Purkinje Refractory Periods
The relative refractory period of the His-Purkinje system could be compared before and after disopyramide in six of the 15 patients who underwent premature atrial stimulation. In the others, this parameter could not be determined either because atrial or AV nodal refractoriness was reached before that of the His-Purkinje system. The relative refractory period of the His-Purkinje system increased in all subjects ( Serial serum concentrations of disopyramide were measured before and 5 and 30 minutes after drug infusion in 21 of the 22 patients. Mean peak disopyramide concentration (5.1 ± 2.2 Ag/ml) occurred 5 minutes after drug administration, and subsequent disopyramide concentrations remained within the reported therapeutic range (2-4 Ag/ml) throughout the study period in all but four patients in whom blood drug concentrations were slightly below 2 Ag/ml at 30 minutes (table 1, fig. 4 ). There was no correlation between measured serum concentrations of drug and changes in H-Q or QRS duration either at 5 or 30 minutes after infusion.
Arrhythmias
The effects of disopyramide on premature ventricular depolarizations were assessed in six of 22 patients (premature ventricular depolarizations ranged from 1-54/min). Premature ventricular depolarizations were completely abolished in four, markedly decreased in one (from 54/min to 4/min), and unchanged in one. In one patient with right bundle branch block, progressively premature ventricular depolarizations during control studies resulted in a single reentrant ventricular depolarization; after disopyramide induced premature ventricular depolarizations, a series (up to six) of reentrant ventricular depolarizations occurred ( fig. 5 ). However, no spontaneous increase in premature ventricular depolarizations or episodes of ventricular tachycardia were noted in this patient after disopyramide.
There was no significant change in blood pressure 5 or 30 minutes after disopyramide administration. In patient 8, severe nausea, emesis, and hypotension developed 5 minutes after disopyramide infusion; the hypotension was transient and required no specific therapy and was believed to represent a vasovagal reaction.
Discussion
Our study clearly establishes the safety of intravenously administered disopyramide in doses designed to achieve therapeutic serum concentrations in patients with bundle branch block. Mean maximal prolongation of H-Q was 18% greater tnan control values 5 minutes after drug infusion, and H-Q tended to return toward control values after 30 minutes. No spontaneous episodes of second degree or third degree AV block were recorded even in patients with markedly prolonged control H-Q intervals ( fig. 1 ). In addition, there was no correlation between baseline H-Q, bundle branch block pattern, QRS duration, or serum disopyramide level and the H-Q increment after disopyramide. In contrast to our previous studies of procainamide in which a substantial lag was often observed between H-Q prolongation and serum blood levels,37 the data for disopyramide suggest that this drug rapidly equilibrates with cardiac tissue producing maximal effects within minutes after drug infusion. (table 3) found that the relative refractory period of the His-Purkinje system increased in the two patients in whom serial measurements could be obtained. Befeler et al.26 described no significant change in the relative refractory period of the His-Purkinje system, but neither the magnitude of the relative refractory period nor the number of patients in whom serial measurements could be obtained was mentioned. In our study, the relative refractory period of the His-Purkinje system increased in all six patients in whom several measurements could be compared (table 3) .
Comparison with Other Antiarrhythmic Agents Our findings support the concept that the electrophysiological effects of disopyramide in man are similar to those of other so-called type I antiarrhythmic agents (quinidine,36 procainamide,37 39, 40 and ajmaline41), in that atrial, His-Purkinje system, and ventricular refractoriness were prolonged as was infranodal conduction time. In addition, the degree of prolongation of the H-Q interval (18%) was similar to that (17%) found for a roughly comparable group of patients with bundle branch block who were studied with intravenous procainamide.37 A previous study of the electrophysiological effects of intravenous administration of quinidine in patients with bundle branch block in our laboratory showed no significant change in the H-Q interval after drug infusion.42 This study was limited in that hypotension (often pronounced) developed in most of the patients and the observed effects were an admixture of direct effects and 
